ReviewCurrent HIV/AIDS reports2025
Current Tools to Diagnose and Predict Hepatocellular Carcinoma: Relevance to HIV and Hepatitis B Virus Coinfection.
Review in Current HIV/AIDS reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPeople with HIV and HBV coinfection have increased risk of developing liver fibrosis and hepatocellular carcinoma (HCC) compared to either infection alone. We review current and emerging tools for HCC diagnosis and prediction in the context of HIV-HBV coinfection. RECENT
findingsTreatment with antiviral therapy and the goal of full viral suppression of both HBV and HIV remains foundational to care for people with HIV-HBV coinfection. All patients with chronic HBV and elevated risk, including cirrhosis or HIV infection, should undergo HCC screening. Tools exist to risk stratify patients with HBV without cirrhosis include PAGE-B, AFP-based tests, GALAD, and ct-DNA liquid biopsy. A limitation is that only PAGE-B has been validated in people with HIV-HBV coinfection. Current tools for HCC detection in people with HIV-HBV coinfection are generally limited to those developed in people with HBV monoinfection, with exception of PAGE-B. Future development of tools to predict and diagnose HCC are needed for people with HIV-HBV coinfection.
Indexed as
Identifiers
41051407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.